(Q53830093)

20 May 2018

title

Cefdinir versus cephalexin for the treatment of skin and skin-structure infections. The Cefdinir Adult Skin Infection Study Group. (English)

1 reference

20 May 2018

1 reference

1 reference

1 reference

Tack KJ

1

1 reference

20 May 2018

Littlejohn TW

2

1 reference

20 May 2018

Mailloux G

3

1 reference

20 May 2018

Wolf MM

4

1 reference

20 May 2018

Keyserling CH

5

1 reference

20 May 2018

publication date

1 March 1998

1 reference

20 May 2018

published in

Clinical Therapeutics

1 reference

20 May 2018

volume

20

1 reference

20 May 2018

issue

2

1 reference

20 May 2018

page(s)

244-256

1 reference

20 May 2018

The diminishing role of the dermatologist in the office-based care of cutaneous diseases.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980088-X

7 January 2021

Therapy with newer oral beta-lactam and quinolone agents for infections of the skin and skin structures: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980088-X

7 January 2021

Antibacterial activities of cefprozil compared with those of 13 oral cephems and 3 macrolides

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980088-X

7 January 2021

In vitro activities of a streptogramin (RP59500), three macrolides, and an azalide against four respiratory tract pathogens

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980088-X

7 January 2021

Decreased activity of erythromycin against Streptococcus pyogenes in Taiwan

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980088-X

7 January 2021

Rapid increase of resistance to erythromycin and clindamycin in Streptococcus pyogenes in Italy, 1993-1995. The Italian Surveillance Group for Antimicrobial Resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980088-X

7 January 2021

In vitro activity evaluations of cefdinir (FK482, CI-983, and PD134393). A novel orally administered cephalosporin.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980088-X

7 January 2021

Comparative in vitro activity and beta-lactamase stability of FK482, a new oral cephalosporin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980088-X

7 January 2021

Study of use of cefdinir versus cephalexin for treatment of skin infections in pediatric patients. The Cefdinir Pediatric Skin Infection Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980088-X

7 January 2021

Suction-induced blister fluid penetration of cefdinir in healthy volunteers following ascending oral doses

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980088-X

7 January 2021

10.1016/S0149-2918(98)80088-X

Identifiers

DOI

1 reference

20 May 2018

1 reference

20 May 2018